Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 3 Clinical and pathological ovarian cancer characteristics determined by the BRCA1 gene status

From: Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients

Status BRCA1 Wild type (n = 108) Germline mutation (n = 17) Statistics p value
Median (range) age at diagnosis in years 56 (28–85) 47 (39–70) −2.859a 0.004
Performance status WHO:
 ▪ 0 15 4   
 ▪ Other 93 13 0.44b 0.51
FIGO stage:
 ▪ Early (I, II) 22 3   
 ▪ Advanced (III,IV) 86 14 0.07b 0.95
Chemotherapy regimen:
 ▪ With paclitaxel 97 16   
 ▪ Without paclitaxel 11 1 0.01b 0.91
Chemotherapy regimen:
 ▪ With cisplatin 47 8   
 ▪ With carboplatin 61 9 0.1c 0.75
Type of histology:
 ▪ Serous 57 11   
 ▪ Other 51 6 0.84c 0.36
Grading:
 ▪ 1 and 2 38 7   
 ▪ 3 and unspecified 70 10 0.23c 0.63
Primary surgery:
 ▪ Optimal (<1 cm) 68 9   
 ▪ Suboptimal (>1 cm) 40 8 0.62c 0.43
  1. aMann–Whitney U test
  2. bYates-corrected Chi-square test
  3. cChi-square test